“…The new merged company is not the only one harmed in this situation, innovation activities of the non-merging rivals do also decrease. While this is oneindustry case specific to pharmaceuticals, there are many other studies questioning the goodness of mergers and acquisitions in terms of various performance metrics such as innovation (Ahuja and Katila, 2001;Cefis and Marsili, 2015;Haucap and Stiebale, 2016;McCarthy and Leendert, 2016;Prabhu et al, 2005), financial performance (Agrawal, 2000;Andre et al, 2004;Datta et al, 1992;King et al, 2004), and managerial perspectives (Bauer and Matzler, 2014) across various industry and country context.…”